MicroSert

Company Overview

Snapshot

Founded in July 2010 by Avraham Shekalim, MicroSert operates with 1–10 employees. The company has secured $806K in total capital across two funding rounds from Mayan Ventures. MicroSert is notable for its development of an easily implantable, refillable, reservoir-type device designed for long-lasting ocular drug release.

Business overview

MicroSert is a Health Tech & Life Sciences company focused on developing an intraocular implant for sustained drug release. Its core technology involves an easily implantable, refillable, reservoir-type device capable of controlled and sustained release of biologic medications for up to two years after implantation. The company intends to apply this versatile drug-delivery platform to treat age-related macular degeneration and diabetic macular edema, serving the medical devices and pharmaceutical industries.

Company Intelligence Q&A

What is MicroSert's primary product?

MicroSert develops an intraocular implant designed for sustained and controlled release of biologic medications within the eye. This device is refillable and can provide drug delivery for up to two years after implantation.

When was MicroSert founded and by whom?

MicroSert was founded in July 2010 by Avraham Shekalim.

What is the total capital raised by MicroSert?

MicroSert has raised a total of $806K across two funding rounds.

What is the status of MicroSert's operations?

MicroSert is currently non-active, having ceased to operate in December 2025.